Development and Testing of New Method for Definitions Hemostasis Parameters in Patients with Mental Pathology

Introduction: hemostasis is one of the most important protective systems of the organism, and its deviations from the norm can lead to fatal results. Changes in hemostasis are observed in many diseases, including mental pathology. In addition, parameters of this system may also change during antipsychotic therapy.

Objective: Development and testing of a new method and device for estimating plasma hemostasis parameters in patients with mental pathologies in order to optimize treatment and eliminate fatal outcomes.

Materials and methods: in the study we used frozen (-80 °C) platelet-free blood plasma (PFP) samples from patients with schizophrenia (16 patients), taken at admission to the clinic FSBSI «Mental Health Research Centre». Plasma coagulation of patients and healthy donors was assessed with the device of our design. Hemostasis assessment is based on the determination of the clot size in proportion to the brightness of the image, which changes as a result of clot formation and lysis.

Results: optimal concentrations of coagulation and fibrinolysis activators, as well as concentrations of calcium ions were determined during the first stage of testing the method and device. The median values of all parameters of coagulation and fibrinolysis except «time before the formation of a clot» in patients upon admission to the clinic were reduced relative with combined plasma donors. The rates of clot formation and lysis in patients are significantly reduced at discharge compared with these parameters at admission. Consequently, these parameters can serve as an estimate of the change in the state of the coagulation and fibrinolysis systems during treatment.

Conclusion: during approbation of the device and method in the process of coagulation and fibrinolysis research in patients with schizophrenia, lower levels of parameters were detected compared to donors, and a decrease in the activity of plasma coagulation and fibrinolysis during treatment with antipsychotics was shown.

1. Zarrabi MH, Zucker S, Miller F, et al. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann. Intern Med. 1979;91(2):194—199. DOI: 10.7326/0003-4819-91-2-194.

2. Carrizo E, Fernandez V, Quintero J, et al. Coagulation and Inflammation Markers During Atypical or Typical Antipsychotic Treatment in Schizophrenia Patients and Drug Free First-degree Relatives Schizophrenia Research. 2008;103(1-3):83-93. DOI: 101016/j.schres.2008.03.004.

3. Masopust J, Maly R, Valis Martin. Risk of venous thromboembolism durintreatment with antipsychotic agents. Psychiatry and Clinical Neurosciences. 2012;66(7):541-552. http://dx.doi.org/10.1111/pcn.12001.

4. Brusov OS, Matveev IA, Kirillov PS i dr. Risk assessment of thrombotic events in patients with schizophrenia and schizoaffective disorder in the acute state: the «fibrinodynamics» technology. Journal of neurology and psychiatry imeni S.S. Korsakova. 2017;11:91-100. (In Russ.). org/10.17116/jnevro20171171191-100 ID: 30765063.

5. Cheremnyh EG, Savin MV, Ras-triga SN i dr. Pribor dlya biologicheskih issledovanij Patent № Ru 2673745, 02.04.2018. (In Russ.).